Head-To-Head Review: IntelliPharmaCeutics Intl (IPCI) vs. Marinus Pharmaceuticals (MRNS)

IntelliPharmaCeutics Intl (NASDAQ: IPCI) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Risk & Volatility

IntelliPharmaCeutics Intl has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500.


This table compares IntelliPharmaCeutics Intl and Marinus Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IntelliPharmaCeutics Intl -205.34% -2,062.11% -135.25%
Marinus Pharmaceuticals N/A -67.76% -55.65%

Analyst Recommendations

This is a summary of current ratings and recommmendations for IntelliPharmaCeutics Intl and Marinus Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IntelliPharmaCeutics Intl 0 2 2 0 2.50
Marinus Pharmaceuticals 0 0 2 0 3.00

IntelliPharmaCeutics Intl presently has a consensus price target of $2.40, suggesting a potential upside of 228.77%. Marinus Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 121.04%. Given IntelliPharmaCeutics Intl’s higher possible upside, equities research analysts clearly believe IntelliPharmaCeutics Intl is more favorable than Marinus Pharmaceuticals.

Earnings and Valuation

This table compares IntelliPharmaCeutics Intl and Marinus Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IntelliPharmaCeutics Intl $2.25 million 10.08 -$10.14 million ($0.35) -2.09
Marinus Pharmaceuticals N/A N/A -$28.64 million ($0.93) -7.05

IntelliPharmaCeutics Intl has higher revenue and earnings than Marinus Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than IntelliPharmaCeutics Intl, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

3.3% of IntelliPharmaCeutics Intl shares are owned by institutional investors. Comparatively, 52.5% of Marinus Pharmaceuticals shares are owned by institutional investors. 6.4% of Marinus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


Marinus Pharmaceuticals beats IntelliPharmaCeutics Intl on 7 of the 12 factors compared between the two stocks.

About IntelliPharmaCeutics Intl

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit